These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 34231442)

  • 61. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
    Gentilella R; Pechtner V; Corcos A; Consoli A
    Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy.
    Meece J
    Adv Ther; 2017 Mar; 34(3):638-657. PubMed ID: 28210986
    [TBL] [Abstract][Full Text] [Related]  

  • 63. GLP-1 receptor agonists in the treatment of polycystic ovary syndrome.
    Lamos EM; Malek R; Davis SN
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):401-408. PubMed ID: 28276778
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
    Elvert R; Herling AW; Bossart M; Weiss T; Zhang B; Wenski P; Wandschneider J; Kleutsch S; Butty U; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Lorenz M; Keil S; Larsen PJ
    Diabetes Obes Metab; 2018 Aug; 20(8):1836-1851. PubMed ID: 29938884
    [TBL] [Abstract][Full Text] [Related]  

  • 65. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
    Farr OM; Sofopoulos M; Tsoukas MA; Dincer F; Thakkar B; Sahin-Efe A; Filippaios A; Bowers J; Srnka A; Gavrieli A; Ko BJ; Liakou C; Kanyuch N; Tseleni-Balafouta S; Mantzoros CS
    Diabetologia; 2016 May; 59(5):954-65. PubMed ID: 26831302
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Semaglutide for the treatment of obesity.
    Chao AM; Tronieri JS; Amaro A; Wadden TA
    Trends Cardiovasc Med; 2023 Apr; 33(3):159-166. PubMed ID: 34942372
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Discovery of a novel GLP-1/GIP dual receptor agonist CY-5 as long-acting hypoglycemic, anti-obesity agent.
    Liu C; Li C; Cai X; Zou Y; Mo J; Chen B; Cai Y; Han T; Huang W; Qian H; Zhang W
    Bioorg Chem; 2021 Jan; 106():104492. PubMed ID: 33268008
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Semaglutide as a promising antiobesity drug.
    Christou GA; Katsiki N; Blundell J; Fruhbeck G; Kiortsis DN
    Obes Rev; 2019 Jun; 20(6):805-815. PubMed ID: 30768766
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective.
    Jensterle M; Janez A; Fliers E; DeVries JH; Vrtacnik-Bokal E; Siegelaar SE
    Hum Reprod Update; 2019 Jul; 25(4):504-517. PubMed ID: 31260047
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Antiobesity efficacy of GLP-1 receptor agonist liraglutide is associated with peripheral tissue-specific modulation of lipid metabolic regulators.
    Decara J; Arrabal S; Beiroa D; Rivera P; Vargas A; Serrano A; Pavón FJ; Ballesteros J; Dieguez C; Nogueiras R; Rodríguez de Fonseca F; Suárez J
    Biofactors; 2016 Nov; 42(6):600-611. PubMed ID: 27213962
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Semaglutide once-weekly: improved efficacy with a new safety warning.
    Coon SA; Crannage EF; Kerwin LC; Guyton JE
    Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1061-1072. PubMed ID: 30296182
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.
    Barnett AH; Arnoldini S; Hunt B; Subramanian G; Hoxer CS
    Diabetes Obes Metab; 2018 Aug; 20(8):1921-1927. PubMed ID: 29652101
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
    Lau J; Bloch P; Schäffer L; Pettersson I; Spetzler J; Kofoed J; Madsen K; Knudsen LB; McGuire J; Steensgaard DB; Strauss HM; Gram DX; Knudsen SM; Nielsen FS; Thygesen P; Reedtz-Runge S; Kruse T
    J Med Chem; 2015 Sep; 58(18):7370-80. PubMed ID: 26308095
    [TBL] [Abstract][Full Text] [Related]  

  • 74. GLP-1 receptor agonists do not affect sodium intake: Exploratory analyses from two randomized clinical trials.
    Smits MM; Ten Kulve JS; van Bloemendaal L; Tonneijck L; Muskiet MHA; Kramer MHH; Ijzerman RG; van Raalte DH
    Nutrition; 2019; 67-68():110524. PubMed ID: 31415908
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy.
    Gomez-Peralta F; Abreu C
    Drug Des Devel Ther; 2019; 13():731-738. PubMed ID: 30863012
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Allelic variant in the glucagon-like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study.
    Chedid V; Vijayvargiya P; Carlson P; Van Malderen K; Acosta A; Zinsmeister A; Camilleri M
    Neurogastroenterol Motil; 2018 Jul; 30(7):e13313. PubMed ID: 29488276
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Role of GLP-1 Receptor Agonists in Pediatric Obesity: Benefits, Risks, and Approaches to Patient Selection.
    Page LC; Freemark M
    Curr Obes Rep; 2020 Dec; 9(4):391-401. PubMed ID: 33085056
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Not Available].
    Fischli S; Henzen C
    Ther Umsch; 2017; 74(8):433-439. PubMed ID: 29461151
    [No Abstract]   [Full Text] [Related]  

  • 79. Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog.
    Gydesen S; Andreassen KV; Hjuler ST; Hellgren LI; Karsdal MA; Henriksen K
    Am J Physiol Endocrinol Metab; 2017 Nov; 313(5):E598-E607. PubMed ID: 28292761
    [TBL] [Abstract][Full Text] [Related]  

  • 80. GLP-1-based therapies to boost autophagy in cardiometabolic patients: From experimental evidence to clinical trials.
    Costantino S; Paneni F
    Vascul Pharmacol; 2019 Apr; 115():64-68. PubMed ID: 30926561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.